- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Janssen Announces Start of Phase 3 Trial for Investigational Respiratory Syncytial Virus (RSV) Vaccine in Older Adults
Positive Phase 2b data supporting further evaluation will be presented at IDWeek 2021
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
Pivotal UNIVERSE study published in the Journal of the American Heart Association Data included in recent New Drug Application submitted to FDA for two pediatric indications
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
Additional data show a booster increases protection 94 percent protection in the U.S. with booster given at two months Four-fold increase in antibodies when given at two months 12-fold increase in antibodies when booster given at six months
Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor
Oral presentation at ESMO Annual Congress 2021 – featured in a late-breaking abstract – reports efficacy and safety of BALVERSA® in combination with a PD-1 inhibitor in bladder cancer
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
Data show the vaccine regimen induced neutralizing antibody responses in nearly all participating adults and children 21 days after the second dose Adults receiving booster shots two years after initial vaccination regimen showed strong immune responses The data support the potential prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect adults and children
Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
Data for approved and investigational treatments to be presented in bladder cancer, lung cancer and prostate cancer Investigational RYBREVANT® (amivantamab-vmjw) and lazertinib combination therapy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to be featured in oral presentations
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines
Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design
The Women in STEM2D (WiSTEM2D) Scholars Award honors female scholars with $150,000 grant and three years of mentorship Deadline for applications is Sept. 27, 2021
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
XARELTO® is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, now including PAD patients post-LER XARELTO® is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation PAD impacts 20 million Americans1 and is the leading cause of amputations in the U.S., with rates continuing to rise2